Aytu BioPharma, Inc.
Symbol: AYTU
NASDAQ
2.9043
USDMarktpreis heute
-0.9631
P/E-Verhältnis
-0.0159
PEG-Verhältnis
16.17M
MRK Kapital
- 0.00%
DIV Rendite
Aytu BioPharma, Inc. (AYTU) Finanzberichte
Bilanz
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 81.66 | 23 | 19.4 | 49.6 | |||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.net-receivables | 122.27 | 28.9 | 21.7 | 28.2 | |||||||||||||||||
balance-sheet.row.inventory | 51.6 | 12 | 10.8 | 16.3 | |||||||||||||||||
balance-sheet.row.other-current-assets | 4.13 | 0.9 | 0.6 | 1 | |||||||||||||||||
balance-sheet.row.total-current-assets | 293.27 | 72.8 | 59.9 | 105.2 | |||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 15.7 | 3.9 | 6.3 | 8.7 | |||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 65.8 | |||||||||||||||||
balance-sheet.row.intangible-assets | 235.49 | 59 | 70.6 | 85.5 | |||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 235.49 | 59 | 70.6 | 151.3 | |||||||||||||||||
balance-sheet.row.long-term-investments | -1.38 | -1.4 | 0 | -10.9 | |||||||||||||||||
balance-sheet.row.tax-assets | 1.38 | 1.4 | 0 | 10.9 | |||||||||||||||||
balance-sheet.row.other-non-current-assets | 3.36 | 0.8 | 0.8 | 0.5 | |||||||||||||||||
balance-sheet.row.total-non-current-assets | 254.55 | 63.6 | 77.7 | 160.4 | |||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-assets | 547.82 | 136.5 | 137.6 | 265.7 | |||||||||||||||||
balance-sheet.row.account-payables | 53.09 | 13.5 | 11 | 19.3 | |||||||||||||||||
balance-sheet.row.short-term-debt | 17.7 | 1.6 | 3.9 | 25.5 | |||||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.long-term-debt-total | 55.92 | 14.7 | 14.3 | 2.8 | |||||||||||||||||
Deferred Revenue Non Current | -1.38 | -1.4 | 0 | -11.2 | |||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 1.38 | - | - | - | |||||||||||||||||
balance-sheet.row.other-current-liab | 82.35 | 7.1 | 49.5 | 7.4 | |||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 118.45 | 28.1 | 27.1 | 18.7 | |||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.capital-lease-obligations | 4.05 | 0.8 | 2.2 | 3.6 | |||||||||||||||||
balance-sheet.row.total-liab | 402.53 | 97.1 | 91.5 | 128.1 | |||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.common-stock | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.retained-earnings | -1230.52 | -304.1 | -288.5 | -178.3 | |||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 1375.81 | 343.5 | 334.6 | 315.9 | |||||||||||||||||
balance-sheet.row.total-stockholders-equity | 145.29 | 39.4 | 46.1 | 137.6 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 547.82 | 136.5 | 137.6 | 265.7 | |||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-equity | 145.29 | 39.4 | 46.1 | 137.6 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 547.82 | - | - | - | |||||||||||||||||
Total Investments | -1.38 | -1.4 | 0 | -10.9 | |||||||||||||||||
balance-sheet.row.total-debt | 73.62 | 16.4 | 18.2 | 28.3 | |||||||||||||||||
balance-sheet.row.net-debt | -8.04 | -6.6 | -1.2 | -21.3 |
Kapitalflussrechnung
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -18 | -17.1 | -110.2 | -58.3 | |||||||||||||||||
cash-flows.row.depreciation-and-amortization | 8.72 | 8.8 | 10.3 | 9.2 | |||||||||||||||||
cash-flows.row.deferred-income-tax | 7.31 | 3.3 | 0 | 22.3 | |||||||||||||||||
cash-flows.row.stock-based-compensation | 3.55 | 6 | 5.2 | 3.6 | |||||||||||||||||
cash-flows.row.change-in-working-capital | 1.71 | -5.8 | -10.9 | 1.7 | |||||||||||||||||
cash-flows.row.account-receivables | -3.79 | -7.2 | 6.5 | 1.5 | |||||||||||||||||
cash-flows.row.inventory | -2.57 | -3.6 | 1.3 | 2.8 | |||||||||||||||||
cash-flows.row.account-payables | 0.19 | 2.4 | -7.7 | -3.2 | |||||||||||||||||
cash-flows.row.other-working-capital | 7.87 | 2.6 | -11 | 0.6 | |||||||||||||||||
cash-flows.row.other-non-cash-items | 2.81 | -0.4 | 76.7 | -4.5 | |||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 6.11 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | 0 | -2.3 | |||||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | -3.2 | -2.8 | |||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.other-investing-activites | -0.4 | -0.1 | -0.1 | 2.4 | |||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -0.4 | -0.1 | -3.2 | -2.8 | |||||||||||||||||
cash-flows.row.debt-repayment | -2.39 | -2.3 | -172.5 | -54.9 | |||||||||||||||||
cash-flows.row.common-stock-issued | 3.93 | 15.6 | 11.7 | 45.1 | |||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.other-financing-activites | -7.22 | -4.4 | 162.3 | 40.2 | |||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -5.68 | 8.9 | 1.5 | 30.3 | |||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.net-change-in-cash | 0.03 | 3.6 | -30.5 | 1.6 | |||||||||||||||||
cash-flows.row.cash-at-end-of-period | 81.66 | 23 | 19.4 | 49.9 | |||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 81.63 | 19.4 | 49.9 | 48.3 | |||||||||||||||||
cash-flows.row.operating-cash-flow | 6.11 | -5.1 | -28.8 | -26 | |||||||||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | 0 | -2.3 | |||||||||||||||||
cash-flows.row.free-cash-flow | 6.11 | -5.1 | -28.8 | -28.3 |
Zeile der Gewinn- und Verlustrechnung
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 98.5 | 107.4 | 96.7 | 65.6 | |||||||||||||||||
income-statement-row.row.cost-of-revenue | 36.2 | 40.8 | 44.4 | 36.4 | |||||||||||||||||
income-statement-row.row.gross-profit | 62.29 | 66.6 | 52.3 | 29.2 | |||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||
income-statement-row.row.research-development | 2.45 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-general-administrative | 25.68 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 34.78 | - | - | - | |||||||||||||||||
income-statement-row.row.other-expenses | -1.94 | -4.8 | 4.1 | 6 | |||||||||||||||||
income-statement-row.row.operating-expenses | 65.31 | 79 | 88.4 | 67.4 | |||||||||||||||||
income-statement-row.row.cost-and-expenses | 101.52 | 119.7 | 132.8 | 103.9 | |||||||||||||||||
income-statement-row.row.interest-income | 0 | 0 | 0 | 0 | |||||||||||||||||
income-statement-row.row.interest-expense | -3.86 | 0 | 147.5 | 0 | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 34.78 | - | - | - | |||||||||||||||||
income-statement-row.row.total-other-income-expensenet | -11.55 | -4.7 | -147.5 | -19.8 | |||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.other-operating-expenses | -1.94 | -4.8 | 4.1 | 6 | |||||||||||||||||
income-statement-row.row.total-operating-expenses | -11.55 | -4.7 | -147.5 | -19.8 | |||||||||||||||||
income-statement-row.row.interest-expense | -3.86 | 0 | 147.5 | 0 | |||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 5.71 | 4.8 | 4.1 | 23.7 | |||||||||||||||||
income-statement-row.row.ebitda-caps | -0.31 | - | - | - | |||||||||||||||||
income-statement-row.row.operating-income | -8.26 | -17.1 | 37.2 | -38.2 | |||||||||||||||||
income-statement-row.row.income-before-tax | -17.17 | -17.1 | -110.3 | -58 | |||||||||||||||||
income-statement-row.row.income-tax-expense | 1.25 | -0.1 | -0.1 | 0.3 | |||||||||||||||||
income-statement-row.row.net-income | -16.64 | -17.1 | -110.2 | -58.3 |
Häufig gestellte Frage
Wie hoch ist die Aytu BioPharma, Inc. (AYTU) Gesamtvermögen?
Aytu BioPharma, Inc. (AYTU) Gesamtvermögen ist 136463000.000.
Wie hoch ist der Jahresumsatz des Unternehmens?
Der Jahresumsatz ist 45033000.000.
Wie hoch ist die Gewinnspanne des Unternehmens?
Die Gewinnmarge des Unternehmens ist 0.632.
Wie hoch ist der freie Cashflow des Unternehmens?
Der freie Cashflow ist 1.108.
Wie hoch ist die Nettogewinnspanne des Unternehmens?
Die Nettogewinnmarge ist -0.169.
Wie hoch sind die Gesamteinnahmen des Unternehmens?
Der Gesamtertrag ist -0.084.
Was ist der Aytu BioPharma, Inc. (AYTU) nettogewinn (reingewinn)?
Der Nettogewinn (Nettoeinkommen) ist -17051000.000.
Wie hoch ist die Gesamtverschuldung des Unternehmens?
Die Gesamtverschuldung ist 16361000.000.
Wie hoch ist der Betriebsaufwand?
Die Betriebsausgaben sind 78961000.000.
Wie hoch ist der Bargeldbestand des Unternehmens?
Die Unternehmensliquidität ist 19529000.000.